BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17489582)

  • 1. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
    Qin Z; Kastrati I; Chandrasena RE; Liu H; Yao P; Petukhov PA; Bolton JL; Thatcher GR
    J Med Chem; 2007 May; 50(11):2682-92. PubMed ID: 17489582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
    Yu B; Dietz BM; Dunlap T; Kastrati I; Lantvit DD; Overk CR; Yao P; Qin Z; Bolton JL; Thatcher GR
    Mol Cancer Ther; 2007 Sep; 6(9):2418-28. PubMed ID: 17876041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator.
    Liu H; Bolton JL; Thatcher GR
    Chem Res Toxicol; 2006 Jun; 19(6):779-87. PubMed ID: 16780356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators.
    Qin Z; Kastrati I; Ashgodom RT; Lantvit DD; Overk CR; Choi Y; van Breemen RB; Bolton JL; Thatcher GR
    Drug Metab Dispos; 2009 Jan; 37(1):161-9. PubMed ID: 18936111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzothiophene and naphthalene derived constrained SERMs.
    Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New scaffolds for the design of selective estrogen receptor modulators.
    Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
    O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
    J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectively targeting estrogen receptors for cancer treatment.
    Shanle EK; Xu W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1265-76. PubMed ID: 20708050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
    Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
    J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation.
    Liu H; Liu J; van Breemen RB; Thatcher GR; Bolton JL
    Chem Res Toxicol; 2005 Feb; 18(2):162-73. PubMed ID: 15720120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
    Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
    J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.
    Makar S; Saha T; Swetha R; Gutti G; Kumar A; Singh SK
    Bioorg Chem; 2020 Jan; 94():103380. PubMed ID: 31757413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
    Mukherjee S; Saha A; Roy K
    Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
    Lv W; Liu J; Skaar TC; O'Neill E; Yu G; Flockhart DA; Cushman M
    J Med Chem; 2016 Jan; 59(1):157-70. PubMed ID: 26704594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridged androstenediol analogs as ER-beta selective SERMs.
    Blizzard TA; Gude C; Chan W; Birzin ET; Mojena M; Tudela C; Chen F; Knecht K; Su Q; Kraker B; Holmes MA; Rohrer SP; Hammond ML
    Bioorg Med Chem Lett; 2007 May; 17(10):2944-8. PubMed ID: 17448656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
    Hummel CW; Geiser AG; Bryant HU; Cohen IR; Dally RD; Fong KC; Frank SA; Hinklin R; Jones SA; Lewis G; McCann DJ; Rudmann DG; Shepherd TA; Tian H; Wallace OB; Wang M; Wang Y; Dodge JA
    J Med Chem; 2005 Nov; 48(22):6772-5. PubMed ID: 16250633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
    Bechmann N; Kniess T; Pietzsch J
    J Med Chem; 2019 Jul; 62(14):6525-6539. PubMed ID: 31099568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.